Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Diabetes is an important risk factor of coronary atherosclerosis, and it's well known that platelets of diabetic patients are hyper reactive and so resistant to common antithrombotic therapy. Moreover, in diabetic patients platelets are characterized by high turnover that is responsible of lack of protection by cardioaspirin at common dosage. The aim of our study is to asses the efficacy of different doses of aspirin in diabetic patients with acute coronary syndrome.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| aspirin 100 mg bis in die | Experimental | aspirin 100 mg twice daily for the first month after acute coronary syndrome |
|
| aspirin 200 mg | Active Comparator | aspirin 200 mg once daily for the first month after acute coronary syndrome |
|
| aspririn 100 mg | Active Comparator | aspirin 100 mg once daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| aspirin 100 mg bis in die | Drug | Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effects of different doses of aspirin on platelet aggregation | Valuation of different doses of aspirin once or twice daily on platelet aggregation after 10 day and 30 day from the acute coronary syndrome | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Valuation of RAC1 levels in platelets | 1 month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Azienda Ospedaliera Universitaria Federico II | Naples | 80131 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| aspririn 200 mg once daily | Drug | Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation. |
|
| aspirin 100 mg once daily | Drug | Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation. |
|
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001241 | Aspirin |
| ID | Term |
|---|---|
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided